Question 1

What is DENOSUMAB-BMWO used for?

Accepted Answer

DENOSUMAB-BMWO (brand name Stoboclo) is a RANKL Inhibitor indicated for defined as a history of osteoporotic fracture, or multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis.

Question 2

How does DENOSUMAB-BMWO work?

Accepted Answer

DENOSUMAB-BMWO works through the following mechanism: 12.1 Mechanism of Action Denosumab products bind to RANKL, a transmembrane or soluble protein essential for the formation, function, and survival of osteoclasts, the cells responsible for bone resorption. Denosumab products prevent RANKL from activating its receptor, RANK, on the surface of osteoclasts and their precursors. Prevention of the RANKL/RANK interaction inhibits osteoclast formation, function, and survival, thereby decreasing bone resorption and increasing bone mass and strength in both cortical and trabecular bone..

Question 3

What are the most common side effects of DENOSUMAB-BMWO?

Accepted Answer

Reported side effects vary by individual. The side-effects section on this page lists the events most frequently reported to FDA FAERS for DENOSUMAB-BMWO. FAERS is voluntary reporting, so it reflects what was reported, not absolute incidence.

Question 4

Is DENOSUMAB-BMWO the same as Stoboclo?

Accepted Answer

Stoboclo is a brand name for DENOSUMAB-BMWO. They share the same active ingredient and FDA-approved indications. Biosimilars and authorised generics may differ in inactive ingredients such as buffers or preservatives.

DENOSUMAB-BMWO

Mechanism of Action

Indications

FDA Warnings

Known Side Effects

Community Discussions

Primary sources

Compare With

Formulations